VBIV240517P2500
- 1.95
- 0.000.00%
VBI Vaccines Newsroom
VBI Vaccines' Promising Glioblastoma Treatment Data
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data From VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company's cancer vaccine immunotherapeutic candidate in recurrent glioblastoma (GBM), were accepted for poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
VBI Vaccines' Revenue Soars, Promising Vaccine Trials
VBI Vaccines Updates Share Sale Agreements and Partnerships
Express News | VBI Vaccines: Entered at Market Offering Deal, Post Which Co May Offer and Sell, From Time to Time Common Shares for Gross Proceeds of up to $8.5 Mln
VBI Vaccines | 10-Q: Quarterly report
Express News | VBI Vaccines Q1 Adjusted Net Income USD -13.57 Million
Express News | VBI Vaccines Q1 Adjusted EPS USD -0.55
Express News | VBI Vaccines Q1 Operating Expenses USD 12.966 Million
VBI Vaccines 1Q Loss/Shr 73c >VBIV
VBI Vaccines 1Q Loss/Shr 73c >VBIV
VBI Vaccines 1Q Loss $17.9M >VBIV
VBI Vaccines 1Q Loss $17.9M >VBIV
Express News | VBI Vaccines Reports First Quarter 2024 Financial Results
Express News | VBI Vaccines Q1 Operating Income USD -11.752 Million
Express News | VBI Vaccines Q1 Revenue USD 1.214 Million
Express News | Perceptive Advisors LLC - Had Previously Reported 5.8% Stake in VBI Vaccines as of Nov 17, 2023
Express News | Perceptive Advisors LLC Reports 4.4% Stake in VBI Vaccines as of April 16 - SEC Filing
Express News | VBI Vaccines Inc : Raymond James Cuts Target Price to $5 From $6
VBI Vaccines FY Non-GAAP EPS of $3.96
VBI Vaccines Soars With Hepatitis B Vaccine Success
VBI Vaccines 2023 Rev $8.7M >VBIV
VBI Vaccines 2023 Rev $8.7M >VBIV